Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension

This study has been completed.

Sponsored by:	Gachon University Gil Medical Center
Information provided by:	Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:	NCT00741078

Purpose

The investigators hypothesized combination therapy would be superior to monotherapy.

Condition	Intervention	Phase
Hypertension	Drug: statin, amlodipine	Phase IV

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Insulin Atorvastatin Atorvastatin calcium Amlodipine Amlodipine besylate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Crossover Assignment
Official Title:	Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension

Further study details as provided by Gachon University Gil Medical Center:

Study Start Date:	December 2004
Study Completion Date:	August 2008

Arms	Assigned Interventions
atorvastatin, amlodipine: Experimental	Drug: statin, amlodipine

Eligibility

Ages Eligible for Study:	25 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Hypertension

Exclusion Criteria:

Chronic renal disease
Severe hypertension

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00741078

Locations

Korea, Republic of
Gil Medical Center
Incheon, Korea, Republic of, 405-760

Sponsors and Collaborators

Gachon University Gil Medical Center

More Information

Study ID Numbers:	GMC-200504
Study First Received:	August 20, 2008
Last Updated:	August 28, 2008
ClinicalTrials.gov Identifier:	NCT00741078
Health Authority:	South Korea: Institutional Review Board

Keywords provided by Gachon University Gil Medical Center:

endothelial
function
insulin
sensitivity

Study placed in the following topic categories:

Calcium, Dietary
Vascular Diseases
Insulin

Atorvastatin
Amlodipine
Hypertension

Additional relevant MeSH terms:

Antimetabolites
Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Antilipemic Agents
Calcium Channel Blockers
Enzyme Inhibitors
Cardiovascular Agents

Anticholesteremic Agents
Antihypertensive Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions
Membrane Transport Modulators
Therapeutic Uses
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009